NRx Pharmaceuticals, Inc.
NRXPNASDAQHealthcare● Active
$4.33
+$0.19(+4.59%)
Market Cap$74847142
P/E Ratio—
52W High$5.055
52W Low$1.62
NRx Pharmaceuticals, Inc. (NRXP) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · NRXP · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $1.23M | $0.00M | $0.00M | $0.00M | $0.00M |
| Cost of Revenue | $0.51M | $0.01M | $0.01M | $0.00M | $0.00M |
| Gross Profit | $0.72M | ($0.01M) | ($0.01M) | ($0.00M) | ($0.00M) |
| Gross Margin %(computed) | 58.78% | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $3.78M | $6.20M | $13.37M | $17.03M | $20.26M |
| G&A Expenses | $13.06M | $0.00M | $0.00M | $0.00M | $0.00M |
| Total Operating Expenses | $16.94M | $19.70M | $27.58M | $44.33M | $95.20M |
| Operating Income | ($16.22M) | ($19.70M) | ($27.59M) | ($44.34M) | ($95.20M) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.01M | $0.04M | $0.49M | $0.25M | $0.00M |
| Interest Expense | $0.67M | $1.08M | $0.12M | $0.00M | $0.02M |
| Income Before Tax | ($28.62M) | ($25.13M) | ($30.15M) | ($39.75M) | ($93.06M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($28.62M) | ($25.13M) | ($30.15M) | ($39.75M) | ($93.06M) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.34 | $-2.39 | $-3.98 | $-0.60 | $-7.44 |
| Wtd Avg Shares | 21.40M | 10.52M | 7.58M | 65.77M | 46.92M |
| EBITDA | ($27.81M) | ($24.04M) | ($30.02M) | ($39.75M) | ($93.04M) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more NRx Pharmaceuticals, Inc. data
About NRx Pharmaceuticals, Inc. (NRXP) Income Statement
NRx Pharmaceuticals, Inc. (NRXP) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, NRXP reported revenue of $0.00B, gross profit of $0.00B (gross margin 58.78%), and net income of ($0.03B) — a net profit margin of -2336.49%.
Frequently asked questions
NRXP · 4 questionsNRx Pharmaceuticals, Inc. (NRXP) reported revenue of $0.00B for 2025, up —% year-over-year.
NRXP revenueNRXP salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09